CRIS

Permanent URI for this communityhttps://scripta.up.edu.mx/handle/20.500.12552/1

Browse

Settings

Language: search.filters.language.EnglishSubject: search.filters.subject.Diabetes

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Ibervillea sonorae (S. Watson) Green a potential resource of bioactive compounds: Systematic analysis of a Mexican plant used in traditional medicine
    (Elsevier, 2025)
    Angulo Molina, Aracely
    ;
    Cristofaro, Valeria di
    ;
    Pieles, Uwe
    ;
    López Romero, Julio César
    ;
    Vidal Gutiérrez, Max
    Ibervillea sonorae (S. Watson) Green (Cucurbitaceae) is a tuber succulent known as “wareke,” which grows in dry desert landscapes in northwestern Mexico and the southwestern United States. Indigenous tribes use I. sonorae as a remedy against cancer, inflammation, rheumatism, skin infections, and diabetes. The great popularity of wareke in traditional medicine has motivated various working groups to investigate its pharmacological properties. The antiproliferative, antitumoral, antifungal, hypoglycemic, antiinflammatory, antioxidant, and antimicrobial potential of this plant has been established. Chemical studies showed that I. sonorae is a potential resource of bioactive compounds, cucurbitacin-type triterpenoids, and phytosterols, the main secondary metabolites. The objective of this chapter is to systematically analyze the phytochemical knowledge of the plant (isolated and identified compounds), describe the biological activities of different extracts, isolated ingredients, and phytopreparations, and discuss their possible applications. ©The authors © 2025 Elsevier Inc.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    De-escalating treatment indications for patients who achieve metabolic goals
    (Elsevier, 2024)
    García-Ulloa, Ana Cristina
    ;
    Jaime-Casas, Salvador
    ;
    Rosado-Lozoya, Johanna S.
    ;
    Serrano-Pérez, Nancy H.
    ;
    Hernández-Juárez, Diana
    Introduction: Robust evidence exists regarding initiation, intensification or modification of treatments. Recommendations to de-escalate therapy are lacking, specifically in diabetes. A successful treatment de-intensification reduces overtreatment, polypharmacy, and risk of adverse effects. Objective: To encompass current recommendations for deprescribing common drugs and create a consensus among health professionals. Methods: We reviewed four databases for deprescribing approaches published between 2010 and 2022. Articles were divided into different groups of drugs (for uric-acid, hypoglycemic, lipid-lowering, and psychotropic drugs).©Elsevier
      16  1